Lokelma Powder, For Suspension
Product Images NDC 0310-1110

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lokelma (NDC 0310-1110). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Figure 1)

Chemical structure diagram of sodium zirconium cyclosilicate. The image displays the molecular framework with atoms represented by spheres, including zirconium (Zr), silicon (Si), and oxygen (O), as labeled in the legend to the right.*

FDA Label Image

Figure 2 (Figure 2)

A forest plot chart depicting the ratio (with 90% confidence intervals) of pharmacokinetic parameters AUC and Cmax for various drugs when co-administered with LOKELMA compared to when administered alone. The drugs listed include amlodipine, atorvastatin and its metabolites, clopidogrel and clopidogrel acid, dabigatran, furosemide, glipizide, levothyroxine and its metabolites, losartan and losartan acid, and warfarin enantiomers. Black and white circles represent different data points on the ratio scale from 0.33 to 3.0.*

FDA Label Image

Figure 3 (Figure 3)

A line graph depicting mean serum potassium levels with 95% confidence intervals over time from acute phase hours to randomized withdrawal phase days. It compares multiple treatment groups: 10 g tid, 5 g qd, 10 g qd, 15 g qd, and placebo, showing changes in potassium levels across each group with sample sizes indicated.*

FDA Label Image

Figure 4 (Figure 4)

A line graph depicting mean serum potassium levels (mEq/L) over time in weeks, with 95% confidence intervals. The graph shows points for Acute Phase Baseline (APBL), Extension Phase Baseline (EPBL), titrated doses, and off treatment. It illustrates fluctuations in potassium levels during treatment and post-treatment phases, with sample sizes noted at intervals. Annotations clarify key time points: APBL, EPBL, Exit (last dose visit), and EOS (end of study).*

FDA Label Image

Image 01

A line graph showing serum potassium levels (mEq/L) with 95% confidence intervals over several days in a clinical study. The x-axis marks screening, dose adjustment, evaluation, and follow-up days; the y-axis shows serum potassium concentration. Data lines compare Lokelma (sodium zirconium cyclosilicate) and placebo groups, indicating changes during the study period.*

FDA Label Image

Lokelma 10 mg Ndc 0310-1110-30 Carton (Lokelma 10mg Ndc0310 1110 30 Carton Pdp)

LOKELMA 10 g powder for oral suspension packaging label showing the product name and generic name sodium zirconium cyclosilicate. The label indicates 10 g per packet, is marked Rx Only, and is labeled by AstraZeneca Pharmaceuticals LP. The package contains 30 packets with visible lot, expiration, and barcode sections.*

FDA Label Image

Lokelma 5 G Ndc 0310-1105-30 Carton (Lokelma 5g Ndc0310 1105 30 Carton Pdp)

LOKELMA 5 g powder for oral suspension packaging label. The label includes the proprietary name, generic name sodium zirconium cyclosilicate, and indicates the package contains 30 packets of 5 g each. It is labeled for prescription use only and manufactured by AstraZeneca Pharmaceuticals LP.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.